Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Prostatic Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Thyroid Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Breast Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Carboplatin 49Etoposide 46Cisplatin 42Topotecan 39Irinotecan 21Paclitaxel 20Nivolumab 15pembrolizumab 13Gemcitabine 13atezolizumab 11Ipilimumab 11durvalumab 9Radiotherapy 9Doxorubicin 7Bevacizumab 7rovalpituzumab tesirine 6etoposide phosphate 6amrubicin 6Psychiatric Rehabilitation 6PM 01183 6Docetaxel 6Counseling 6trilaciclib 5Temozolomide 5Sunitinib 5Platinum 5Imatinib Mesylate 5Cyclophosphamide 5Bortezomib 5130-nm albumin-bound paclitaxel 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Small Cell Lung Carcinoma × IT-101 × Clear all
NCT02769962 2025-07-28

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
45 enrolled 30 charts
GenitourinaryThoracic

Carcinoma, Transitional Cell, Lung Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡